CNS Therapeutics | Advancing Intrathecal Pharmaceuticals Gablofen® (intrathecal baclofen)

This site is for U.S. Healthcare Providers

  • Prescribing Info
  • Ordering info
  • Home
  • About Gablofen
  • Company Information
  • News
  • Contact Us
  • Prescribing Info
  • Ordering info
  • Gablofen v Lioresal
  • Reimbursement
  • Refill Convenience Kit
  • Common Questions
View prescribing info »

Comprehensive reimbursement.

Gablofen® can be billed using existing reimbursement codes.

Gablofen is the only brand available in four concentrations: 50 mcg/mL (screening dose), 500 mcg/mL, 1,000 mcg/mL, and 2,000 mcg/mL.

Intrathecal baclofen centers should use the following pre-existing intrathecal baclofen codes with Gablofen:

  • J0475 Injection, baclofen, 10 mg
  • J0476 Injection, baclofen, 50 mcg for intrathecal trial (screening)

Reimbursement coverage for Gablofen includes Medicaid and Medicare Parts B and D.

Contact us for more information about reimbursement.

More choices.

Gablofen® (baclofen injection) is the only brand available in four concentrations.

Learn More »

Order your way.

Order Gablofen through major drug wholesalers or directly from CNS Therapeutics.

Ordering is easy »

Simplifying refills.

Learn more »

IMPORTANT RISK INFORMATION

INDICATIONS AND USAGE

  • Gablofen (baclofen injection) is a gamma-aminobutyric acid (GABA) ergic agonist indicated for use in the management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above.
  • Gablofen should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable central nervous system side effects at effective doses.
  • Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump.
  • Spasticity due to traumatic brain injury: wait at least one year after injury before considering Gablofen therapy.

WARNING: DO NOT DISCONTINUE ABRUPTLY

Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death.

Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g. spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional post-implant clinician and patient information.

CONTRAINDICATIONS

  • Hypersensitivity to baclofen.
  • Do not use Gablofen for intravenous, intramuscular, subcutaneous or epidural administration.

WARNINGS AND PRECAUTIONS

  • Use only with Medtronic SynchroMed® II Programmable Pump or other pumps labeled for intrathecal administration of Gablofen (baclofen injection).
  • Risk of life-threatening overdose during pump refills. Use extreme caution when filling the Medtronic SynchroMed® II Programmable pump, which is equipped with an injection port that allows direct access to the intrathecal catheter. Direct injection into the catheter through the catheter access port may cause a life-threatening overdose.
  • Resuscitative equipment and trained staff must be available during screening dose, dose titration, and refills due to the potential for life-threatening CNS depression, cardiovascular collapse, and/or respiratory failure.

WARNINGS AND PRECAUTIONS (CONTINUED)

  • Overdose may cause drowsiness, lightheadedness, dizziness, somnolence, respiratory depression, seizures, rostral progression of hypotonia, and loss of consciousness progressing to coma.
  • Use with caution in patients with psychotic disorders, schizophrenia, or confusional state, as it may exacerbate condition(s).
  • Fatalities have been reported with intrathecal baclofen use.
  • Caution should be used in patients with a history of autonomic dysreflexia.
  • Presence of infection may increase the risk of surgical complication and complicate dosing of Gablofen.
  • May cause drowsiness: use caution in operation of automobiles, dangerous machinery and activity that made hazardous by decreased alertness. Other CNS depressants and alcohol may add to this effect.
  • Potential for intrathecal mass formation. Clinicians should monitor for signs and symptoms of new neurologic symptoms including the use of imagining diagnostic modalities.
  • Oral baclofen use has been associated with a dose-related increase in incidence of ovarian cysts.
  • Pregnancy Category C. The effect of baclofen in labor and delivery is unknown.
  • Balcofen is excreted into breast milk at oral therapeutic doses.
  • Pediatric use: Safety and effectiveness in pediatric patients below the age of 4 years have not been established.

Serious Adverse Events

  • Sudden withdrawal of Gablofen can result in serious complications that include high fever, confusion, muscle stiffness, multiple organ-system failure, and death. Inform patients that early symptoms of Gablofen withdrawal may include increased spasticity, itching, and tingling of extremities. If Gablofen withdrawal or a pump malfunction is suspected, patients should be brought immediately to a hospital for assessment and treatment.
  • Gablofen overdose may occur suddenly or insidiously. Symptoms may include confusion, drowsiness, lightheadedness, dizziness, slow or shallow breathing, seizures, loss of muscle tone, loss of consciousness, and coma.
  • Other serious adverse events may include: potential for intrathecal mass formation, drainage, infection, meningitis, unmanageable trunk control, CSF leakage, coma, and death.

Common Adverse Events

  • The most common adverse reactions in patients with spasticity of spinal origin were hypotonia (25.3%), somnolence (20.9%), dizziness, nausea/vomiting, hypotension, headache, and convulsions.
  • The most common adverse reactions in patients with spasticity of cerebral origin were hypotonia (34.7%), somnolence (18.7%), headache (10.7%), agitation, constipation, leukocytosis, chills, and urinary retention.
  • Other common adverse events may include hypoventilation, hypertonia, paresthesia, increased salivation, back pain, pruritus, diarrhea, peripheral edema, asthenia, pain, confusion, speech disorder, amblyopia, accidental injury, and dry mouth.

To order: (866) 417 9161
CNS Therapeutics: (651) 207 6959

  • Terms of Use
  • Privacy Policy
  • Code of Conduct
  • Site Map

CNS Therapeutics, Inc.
332 Minnesota St.
St. Paul, MN 55101

© 2013 CNS Therapeutics, Inc. January 2013
All rights reserved. | PRT-105

Ingenuity. Pure and Simple. and Gablofen are registered trademarks of CNS Therapeutics, Inc.

ITB Therapy is a service mark of Medtronic, Inc.

Lioresal and SynchroMed are registered trademarks of Medtronic, Inc.

ChloraPrep is a registered trademark of CareFusion 2200, Inc.

Aplicare is a registered trademark of Clorox Professional Products Company.

Scroll down for additional important risk information

WARNING: DO NOT DISCONTINUE ABRUPTLY

Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death.

Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g. spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional post-implant clinician and patient information.